Management of chronic hepatitis C virus infection in patients with end-stage renal disease: a review

Therapeutics and Clinical Risk Management
Jonathan Aguirre ValadezAldo Torre

Abstract

Infection with hepatitis C virus (HCV) is highly prevalent in chronic kidney disease (CKD) patients, mainly in those on hemodialysis (HD). The seroprevalence of HCV in developing countries ranges between 7% and 40%. Risk factors for this infection in the CKD population include the number of blood transfusions, duration of end-stage renal disease (ESRD), and prevalence of HCV in HD. Chronic HCV infection in patients with ESRD is associated with an increase in morbidity and mortality in the pre and post kidney transplant periods. The increase in mortality is directly associated with liver complications and an elevated cardiovascular risk in HCV-infected patients on hemodialysis. Antiviral treatment may improve the prognosis of patients with HCV, and standard interferon remains the cornerstone of treatment. Treatment of HCV in patients with CKD is complex, but achieving a sustained viral response may decrease the frequency of complications after transplantation. It appears that HCV-infected patients who remain on maintenance dialysis are at increased risk of death compared with HCV patients undergoing renal transplantation.

Citations

Jan 29, 2016·Journal of Viral Hepatitis·A StubbsM Mutchnick
Apr 22, 2016·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·Elise J SmoldersDavid M Burger
Oct 8, 2016·Transplant International : Official Journal of the European Society for Organ Transplantation·Lionel RostaingNassim Kamar

❮ Previous
Next ❯

Datasets Mentioned

BETA
ABT-450

Methods Mentioned

BETA
biopsy
biopsies

Related Concepts

Related Feeds

Antivirals

Antivirals are medications that are used specifically for treating viral infections. Discover the latest research on antivirals here.

Antivirals (ASM)

Antivirals are medications that are used specifically for treating viral infections. Discover the latest research on antivirals here.